长春高新(000661.SZ)：子公司GenSci134注射液境内生产药品注册临床试验申请获得批准

Core Viewpoint - Changchun High-tech (000661.SZ) announced that its subsidiary, Changchun JinSai Pharmaceutical Co., Ltd. (referred to as "JinSai Pharmaceutical"), has received the Clinical Trial Approval Notification from the National Medical Products Administration for its GenSci134 injection, marking a significant step in the development of a treatment for growth hormone deficiency (GHD) [1] Company Summary - JinSai Pharmaceutical's GenSci134 injection is an independently developed Class 1 biological product intended for the treatment of GHD, including adult growth hormone deficiency (AGHD), pediatric growth hormone deficiency (PGHD), and non-GHD patients [1] - The current application specifically targets the treatment of pediatric growth retardation (PGHD) caused by endogenous growth hormone deficiency [1]